Conditions: Hepatitis C, Chronic
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 1013
Healthy volunteers: no

Brief summary:
This multi-center study will evaluate the viral response in patients with chronic hepatitis C, genotype 1, 2, 3 \& 4 on standard anti-viral treatment with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin). Patients will receive weekly subcutaneous Pegasys plus daily oral Copegus for 24 weeks (genotype 2 \& 3) or 48 weeks (genotype 1 \& 4). Patients identified as slow responders/non-rapid virological responders will be eligible for an additional 24 weeks of treatment.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: peginterferon alfa-2a [Pegasys] intervention 2: ribavirin [Copegus]
Intervention descriptions: intervention 1: standard treatment, subcutaneously weekly intervention 2: standard treatment, orally daily

Protocol document: